Bio-IT World 2026 Recap: The Agents Are Here But Is the Foundation Ready?

At Bio-IT World in Boston last month, one thing was impossible to miss: everyone is talking about agents.

Every booth and hallway conversation circled back to the same theme. Agentic AI is here, and pharma needs to move fast.

The energy was real. The urgency was real. But as I walked the floor, one question kept coming to mind. If everyone is building agents, who is making sure those agents actually know what they are talking about?

I presented on exactly this topic. My session was titled “Radically Accelerate Drug Discovery and Development Using Agentic AI”. What follows are my observations from the event, the key points from my presentation, and what I believe the industry is still getting wrong.

The Problem Has Not Changed. The Patience for It Has.

Let me start with the facts that every pharma leader in that room already knows. It takes 10 to 15 years and billions of dollars to bring a single drug to market. Attrition rates remain devastating, while the underlying R&D data infrastructure across many organizations is still fragmented, siloed, and built on a patchwork of legacy systems, point solutions, and vendor-specific formats.

I have spent over 15 years building data and AI infrastructure for some of the world’s largest biopharma companies and I continue to see the same recurring obstacles:

• Slow adoption of data science and AI across organizations
• Data silos that prevent a unified view across R&D functions
• Fragmented datasets that make cross-domain reasoning difficult
• A time-consuming, error-prone knowledge-to-decision cycle

The industry has made meaningful progress. We built enterprise data management platforms, implemented common data model and ontologies for harmonizing real-world-data (RWD), developed knowledge graphs, and invested heavily in standardized pipelines. But none of these efforts fully broke through the productivity barrier because pharma does not need more disconnected point solutions. It needs a unified, AI-native knowledge architecture. That is what made Bio-IT 2026 feel like a genuine inflection point.

The Floor Was Full of Agents. The Foundation Was Mostly Missing.

Walking the exhibit hall and attending sessions, I noticed something striking: nearly every vendor was showcasing agents or data management solutions.

But I kept asking the same question. What is the agent grounded in?

The answer, more often than not, was vague. A general-purpose LLM. A retrieval layer built on top of a single data source. A vector database pointed at a handful of documents. In some cases, nothing beyond the model’s own parametric memory.

This is the part of the Agentic AI conversation that the industry is not having loudly enough.

Building the agent is actually the easier part. The difficult and truly differentiating challenge is building the enterprise knowledge foundation that empowers those agents to reason reliably across the complexity of pharma R&D.

Without that foundation organizations risk deploying systems that hallucinate, generate incorrect scientific conclusions, or provide misleading recommendations about trial populations, drug interactions, or regulatory precedent. In a regulated, patient-impacting environment, that is not a minor inconvenience. It is a fundamental trust issue.

The FDA Has Already Signaled the Direction

One of the most important points I made in my presentation is something I believe the industry still underestimates: the regulatory direction is already becoming clear. The recent FDA announcement regarding its initiative to advance the implementation of real-time clinical trials (RTCT) is a significant step forward for the industry. The announcement has been direct: for 60 years, clinical trials have been conducted the same way, with key data signals taking years to reach the FDA. That lag time delays regulatory decisions and slows the drug development timeline unnecessarily. The FDA has stated clearly that with improvements in AI and data science, sponsors and trial sites have the opportunity to conduct real-time trials that enhance safety monitoring and radically increase efficiency. This matters.

This is the FDA not merely permitting AI-enabled trial intelligence. It is signaling where the industry is heading. The FDA also released a Request for Information (RFI) regarding a proposed pilot program for RTCT that will launch this summer.  Real-time clinical trial intelligence, adaptive trial designs, and AI-generated evidence are no longer hypothetical. They are the next paradigm. The organizations building the data and AI infrastructure today will be the ones positioned to run the trials of tomorrow.

The Hardest Problem Is Still the Knowledge Layer

Most large pharma companies are already experimenting with building their own agents, and that is the right instinct. But most of those same companies cannot feasibly build their own enterprise knowledge base or AI-powered Data Operating System from scratch. Not at the scale, depth, and governance quality required to support trustworthy Agentic AI across R&D.

This is the gap that ChapsVision is designed to address. ArgonOS, our AI-powered Data Operating System, handles the full data lifecycle: preparation, manipulation, interrogation, intelligence, and decisioning. It adapts to complex pharma ontologies without the rigidity of closed platforms, maintains traceable data lineage across every transformation, and is purpose-built to power the next generation of Agentic AI frameworks.

Together with Sinequa’s advanced agentic knowledge retrieval layer and ChapsAgents’ agentic orchestration engine, it forms the full stack that turns fragmented enterprise data into a governed, agentic organization.

Conclusion

Bio-IT 2026 confirmed something important: AI has genuinely picked up the pace in life sciences. The conversations have shifted from whether to explore this technology to how to scale it. That is a meaningful and encouraging change.

But the most important thing I observed on that floor was also the most underappreciated: the difference between Agentic AI that impresses in a demo and Agentic AI that actually earns the trust of scientists, regulators, and patients is not the agent itself. It is what the agent is built on.

Building agents is the visible, exciting part. Building the governed, enterprise-wide knowledge layer that makes those agents reliable is the difficult work — and ultimately the work that will separate organizations transforming drug development from those still running disconnected pilots years from now.

The tools exist. The regulatory direction is clear. The urgency is real. The question is whether you are building on solid ground.

If you attended Bio-IT and would like to continue the conversation, or if you would like to explore how ChapsVision’s Agentic AI platform applies to your organization, I would love to connect.